TITLE

Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy

AUTHOR(S)
Kim, Tark; Choi, Sang-Ho; Kim, Sung-Han; Jeong, Jin-Yong; Woo, Jun; Kim, Yang; Sung, Heungsup; Kim, Mi-Na; Yoon, Dok; Suh, Cheolwon; Lee, Sang-Oh
PUB. DATE
February 2013
SOURCE
Annals of Hematology;Feb2013, Vol. 92 Issue 2, p231
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma. We estimated the point prevalence of Pneumocystis pneumonia in non-Hodgkin lymphoma patients according to the number of R-CHOP cycles and investigated whether cytoreduction by chemotherapy is associated with Pneumocystis pneumonia development. We retrospectively established a cohort of patients who received R-CHOP for non-Hodgkin lymphoma in our institution. Using this cohort, we estimated the incidence rate and point prevalence of definite and probable Pneumocystis pneumonia. To assess factors associated with Pneumocystis pneumonia development several clinical variables, including absolute neutrophil and lymphocyte count at the time of non-Hodgkin lymphoma diagnosis and when the last R-CHOP cycle was administered, were compared between patients with and without Pneumocystis pneumonia. Of 713 patients in the cohort, 14 and 18 patients were diagnosed with definite and probable Pneumocystis pneumonia, respectively. The overall incidence of definite and definite plus probable PCP in NHL patients receiving R-CHOP were 2.0 % (14/713; 95 % CI, 1.1-3.3 %) and 4.5 % (32/713; 95 % CI, 3.2-6.4 %), respectively. This corresponded to 3.8 (95 % CI, 2.2-6.4) and 8.4 (95 % CI, 5.9-11.9) per 1000 persons. Many cases of Pneumocystis pneumonia (22/32, 68.7 %) developed after administration of the fourth R-CHOP cycle. However, there was no statistical difference in Pneumocystis pneumonia prevalence between patients receiving four or more cycles of R-CHOP and fewer than. Higher absolute neutrophil count (4,742/mm vs. 2,627/mm; p < 0.01) was associated with Pneumocystis pneumonia development at the last R-CHOP cycle, while absolute lymphocyte count at the time of NHL diagnosis was not. Contrary to expectations, Pneumocystis pneumonia is not a frequent complication of R-CHOP treatment for non-Hodgkin lymphoma. Cytoreduction of R-CHOP might not be a risk factor of Pneumocystis pneumonia development. Universal prophylaxis against Pneumocystis pneumonia during R-CHOP treatment could not be strongly recommended.
ACCESSION #
85011521

 

Related Articles

  • Antineoplastics.  // Reactions Weekly;4/13/2013, Issue 1448, p6 

    The article presents case studies of 21 men and 11 women aged 32 to 81 years old who were diagnosed with Pneumocystis jirovecii pneumonia (PCP) after undergoing R-CHOP chemotherapy for non-Hodgkin lymphoma.

  • Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Wästerlid, T.; Brown, P.N.; Hagberg, O.; Hagberg, H.; Pedersen, L.M.; D'Amore, F.; Jerkeman, M. // Annals of Oncology;Jul2013, Vol. 24 Issue 7, p1879 

    Background Standard treatment of adult Burkitt lymphoma is not defined due to the lack of randomised trials. In this situation, population-based data may represent a useful contribution in order to identify an optimal treatment strategy. Patients and methods The aims of this study were to...

  • Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. Jiang, Xuqin; Mei, Xiaodong; Feng, Di; Wang, Xiaojing // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Pneumocystis jiroveci pneumonia (PCP) is frequently reported in lymphoma patients treated with rituximab-contained regimens. There is a trend toward a difference in PCP risk between bi- and tri-weekly regimens. The aims of this systemic review and meta-analysis were to estimate the risk for PCP...

  • Pneumocystis carinii pneumonia.  // MMWR: Morbidity & Mortality Weekly Report;6/27/1997 Supplement RR-12, Vol. 46, p4 

    Provides information on the disease pneumocystis carinii pneumonia. Recommendation made by authorities relating to the prevention of exposure to disease; Precautions that should be considered by adolescents, adults and pregnant women.

  • Prednisolone/rituximab.  // Reactions Weekly;11/2/2013, Issue 1476, p30 

    The article presents a case study of an infant who suffered from pneumocystis carinii pneumonia (PCP) while being treated with prednisolone and rituximab for autoimmune haemolytic anaemia (AIHA).

  • Antineoplastics.  // Reactions Weekly;12/15/2012, Issue 1432, p8 

    The article describes the case of a man who developed pneumocystis pneumonia (PCP) while under chemotherapy for advanced gastric cancer.

  • Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Ahmadi, T; McQuade, J; Porter, D; Frey, N; Loren, A W; Goldstein, S C; Svoboda, J; Stadtmauer, E; Schuster, S J; Nasta, S D // Bone Marrow Transplantation;Aug2012, Vol. 47 Issue 8, p1082 

    We retrospectively analyzed 44 patients undergoing first-line treatment for mantle cell lymphoma with R-HyperCVAD, with or without rituximab (R) maintenance or auto-SCT. The primary study end point was PFS; secondary end point was overall survival.Median follow up for all patients was 3.3 years....

  • Antineoplastics.  // Reactions Weekly;3/3/2007, Issue 1141, p7 

    The article presents a case study on the development of pneumocystis carinii pneumonia in six patients during treatment with antineoplastics for non-Hodgkin's lymphoma. The six patients were receiving rituximab plus CHOEP-14. Pneumocystis carinii pneumonia was diagnosed by polymerase chain...

  • Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis? Besada, Emilio; Nossent, Johannes // Clinical Rheumatology;Nov2013, Vol. 32 Issue 11, p1677 

    Reports in haematology, transplantation medicine and rheumatology indicate that Rituximab, a B cell depleting therapy, increases the risk for Pneumocystis jiroveci pneumopathy. Patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis have an increased incidence of P....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics